Alnylam Pharmaceuticals (ALNY) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The DemonsTTRate study is a long-term, real-world project that follows adults with transthyretin amyloidosis with cardiomyopathy who receive routine care. It aims to track patient profiles, care patterns, quality of life, and system costs, while comparing long-term outcomes on Alnylam’s drug vutrisiran versus other approved options.
The main treatment of interest is vutrisiran, a medicine designed to lower harmful transthyretin protein levels that damage the heart. The study also includes patients on other standard ATTR-CM drugs, giving investors a head-to-head view of how vutrisiran stacks up in everyday practice.
This is an observational, prospective cohort study with no random assignment or blinding, so doctors and patients choose treatments as usual. The primary goal is to understand how different therapies perform in real clinics over time, rather than to test a fixed protocol like a classic drug trial.
The study was first submitted in November 2025, marking the formal launch of this global registry effort. The latest update in March 2026 signals that the protocol and recruitment status are current, which matters for investors tracking execution risk and data timelines.
Recruitment is ongoing, so primary and final completion dates are still in the future and not yet reported. As those dates approach, the market will look for signals on data readout timing, which can move ALNY’s stock on expectations for label expansion, uptake, and competitive pressure.
For Alnylam, strong real-world data showing better outcomes or lower resource use could support broader vutrisiran adoption and strengthen its competitive edge against other ATTR-CM players. Weak or mixed signals could weigh on sentiment, especially as rival therapies from larger cardiovascular names fight for share in this growing, high-value niche.
The DemonsTTRate study is actively recruiting and recently updated, and investors can find further details and ongoing changes on the ClinicalTrials portal.
To learn more about ALNY’s potential, visit the Alnylam Pharmaceuticals drug pipeline page.